Cargando…
TRIM21—From Intracellular Immunity to Therapy
Tripartite motif containing-21 (TRIM21) is a cytosolic ubiquitin ligase and antibody receptor that provides a last line of defense against invading viruses. It does so by acting as a sensor that intercepts antibody-coated viruses that have evaded extracellular neutralization and breached the cell me...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722209/ https://www.ncbi.nlm.nih.gov/pubmed/31555278 http://dx.doi.org/10.3389/fimmu.2019.02049 |
_version_ | 1783448486096666624 |
---|---|
author | Foss, Stian Bottermann, Maria Jonsson, Alexandra Sandlie, Inger James, Leo C. Andersen, Jan Terje |
author_facet | Foss, Stian Bottermann, Maria Jonsson, Alexandra Sandlie, Inger James, Leo C. Andersen, Jan Terje |
author_sort | Foss, Stian |
collection | PubMed |
description | Tripartite motif containing-21 (TRIM21) is a cytosolic ubiquitin ligase and antibody receptor that provides a last line of defense against invading viruses. It does so by acting as a sensor that intercepts antibody-coated viruses that have evaded extracellular neutralization and breached the cell membrane. Upon engagement of the Fc of antibodies bound to viruses, TRIM21 triggers a coordinated effector and signaling response that prevents viral replication while at the same time inducing an anti-viral cellular state. This dual effector function is tightly regulated by auto-ubiquitination and phosphorylation. Therapeutically, TRIM21 has been shown to be detrimental in adenovirus based gene therapy, while it may be favorably utilized to prevent tau aggregation in neurodegenerative disorders. In addition, TRIM21 may synergize with the complement system to block viral replication as well as transgene expression. TRIM21 can also be utilized as a research tool to deplete specific proteins in cells and zebrafish embryos. Here, we review our current biological understanding of TRIM21 in light of its versatile functions. |
format | Online Article Text |
id | pubmed-6722209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67222092019-09-25 TRIM21—From Intracellular Immunity to Therapy Foss, Stian Bottermann, Maria Jonsson, Alexandra Sandlie, Inger James, Leo C. Andersen, Jan Terje Front Immunol Immunology Tripartite motif containing-21 (TRIM21) is a cytosolic ubiquitin ligase and antibody receptor that provides a last line of defense against invading viruses. It does so by acting as a sensor that intercepts antibody-coated viruses that have evaded extracellular neutralization and breached the cell membrane. Upon engagement of the Fc of antibodies bound to viruses, TRIM21 triggers a coordinated effector and signaling response that prevents viral replication while at the same time inducing an anti-viral cellular state. This dual effector function is tightly regulated by auto-ubiquitination and phosphorylation. Therapeutically, TRIM21 has been shown to be detrimental in adenovirus based gene therapy, while it may be favorably utilized to prevent tau aggregation in neurodegenerative disorders. In addition, TRIM21 may synergize with the complement system to block viral replication as well as transgene expression. TRIM21 can also be utilized as a research tool to deplete specific proteins in cells and zebrafish embryos. Here, we review our current biological understanding of TRIM21 in light of its versatile functions. Frontiers Media S.A. 2019-08-28 /pmc/articles/PMC6722209/ /pubmed/31555278 http://dx.doi.org/10.3389/fimmu.2019.02049 Text en Copyright © 2019 Foss, Bottermann, Jonsson, Sandlie, James and Andersen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Foss, Stian Bottermann, Maria Jonsson, Alexandra Sandlie, Inger James, Leo C. Andersen, Jan Terje TRIM21—From Intracellular Immunity to Therapy |
title | TRIM21—From Intracellular Immunity to Therapy |
title_full | TRIM21—From Intracellular Immunity to Therapy |
title_fullStr | TRIM21—From Intracellular Immunity to Therapy |
title_full_unstemmed | TRIM21—From Intracellular Immunity to Therapy |
title_short | TRIM21—From Intracellular Immunity to Therapy |
title_sort | trim21—from intracellular immunity to therapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6722209/ https://www.ncbi.nlm.nih.gov/pubmed/31555278 http://dx.doi.org/10.3389/fimmu.2019.02049 |
work_keys_str_mv | AT fossstian trim21fromintracellularimmunitytotherapy AT bottermannmaria trim21fromintracellularimmunitytotherapy AT jonssonalexandra trim21fromintracellularimmunitytotherapy AT sandlieinger trim21fromintracellularimmunitytotherapy AT jamesleoc trim21fromintracellularimmunitytotherapy AT andersenjanterje trim21fromintracellularimmunitytotherapy |